Benzonatate

The Alitair Pharmaceuticals Executive Team would like to wish our shareholders and stakeholders a Happy New Year! To kick off the year, Alitair will be participating in the J.P. Morgan Healthcare Conference in San Francisco, CA from January 11th - 15th. This is one of the preeminent meetings in 2020 for biopharma and it is a great way to start the year. Alitair will be meeting with both potential funders (as we seek capital to drive the product development program forward) and potential partners (as we seek to identify value-creating transactions for our pipeline assets). Specifically, we seek biopharma companies who wish to license, co-develop or co-commercialize our valuable assets. Current efforts are focused on our lead assets benzonatate polacrilex tablets and the Overdose Reduction (ODR) formulation technology. To schedule a meeting at JPM, contact Frank Koos, SVP, Corporate and Business Development at fkoos@alitair.com. Once Alitair gains additional capital, our team plans to immediately re-initiate product development of benzonatate and ODR. The team also plans to conduct 2 small IP programs to further strengthen our intellectual property. We have one of our most exciting assets, ALT-09 (erdosteine), poised to move ahead following the IP work. This is a pipeline asset with an open IND and is a Phase II-ready Orphan Drug focused on bronchiectasis in both the non-Cystic Fibrosis and Cystic Fibrosis patient populations. Our commitment to bring our products to patients remains strong. It is our passion. Likewise, our commitment to shareholders remains very strong. Looking further into 2020 (and beyond), we seek to reach meaningful transaction points that will significant grow our firm's valuation and that may ultimately unlock additional shareholder value. We express our gratitude to our shareholders for their initial investments in Alitair and we deeply appreciate everyone's patience as we work on executing the business plan.